2008
DOI: 10.1590/s0102-86502008000600010
|View full text |Cite
|
Sign up to set email alerts
|

Clinical research on new drugs (Phase I). Profile of scientific publications: data from the pre-clinical phase and bioethical aspects

Abstract: PURPOSE: To trace a profile of scientific publications, phase I, in order to know whether or not they show pre-clinical phase data, emphasizing bioethical aspects. METHODS: Sixty-one scientific articles, published in 2007, involving research in human beings using new drugs, medicines and vaccines during phase I were analysed. A schedule for data collection was elaborated in which it would be possible to analyse and evaluate those articles. The schedule included items related to the pre-clinical phase associate… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2011
2011
2017
2017

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…12 In Brazil, dabigatran etexilate is not distributed by the Unified Health System (SUS), nor is it standardized in many hospitals, which hinders the monitoring of its use. Thus, the objective of the present study includes the assessment of safety, effectiveness, and adherence to dabigatran prescribed to non-valvular atrial fibrillation in a public Brazilian hospital, specialized in cardiology, by characterizing the profile of adverse events.…”
Section: Introductionmentioning
confidence: 99%
“…12 In Brazil, dabigatran etexilate is not distributed by the Unified Health System (SUS), nor is it standardized in many hospitals, which hinders the monitoring of its use. Thus, the objective of the present study includes the assessment of safety, effectiveness, and adherence to dabigatran prescribed to non-valvular atrial fibrillation in a public Brazilian hospital, specialized in cardiology, by characterizing the profile of adverse events.…”
Section: Introductionmentioning
confidence: 99%